A comparative study of Aldactone and Diane in the treatment of hirsutism.
A comparative study has been performed in order to evaluate the relative potency of Diane and Aldactone in reducing hair growth as well as the effect on blood hormone concentrations. Thirty-six women participated in the study and depending on the desire for contraception, 22 were treated with Diane and 14 with Aldactone. The results show that Aldactone (50 mg per day) had little effect on hormone concentrations, only LH was significantly reduced after 12 months of treatment. Despite the lack of effect on hormone levels, all 14 women reported reduced hair growth and after 5 months of treatment, 58% also reported a decrease in the formation in new hair growth. In contrast to the Aldactone treated group, the women on Diane medication demonstrated a marked decrease in circulating hormone levels with a subsequent effect on the hair parameters. The clinical effects were, however, not quite of the same degree as those seen with Aldactone treatment. Approximately 20% exhibited no response for any of the 3 hair-parameters (reduced hair growth, formation of new hair and a change to softer hair). The response time before any effect was observed was also longer than that seen with the Aldactone group. The data suggest that, at the dosages employed, Aldactone has a better clinical effect on the hair parameters despite a lack of effect on circulating hormone levels. One should, however, be aware that Diane contains only 2 mg cyproterone acetate (CPA) and a better effect would most probably have been obtained using a higher dosage of CPA.
D000293:Adolescent; D000328:Adult; D003534:Cyproterone / Q000627:therapeutic use*; D017373:Cyproterone Acetate; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D010908:Pituitary Hormones, Anterior / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013148:Spironolactone / Q000627:therapeutic use*
D004338:Drug Combinations; D012739:Gonadal Steroid Hormones; D010908:Pituitary Hormones, Anterior; D012738:Sex Hormone-Binding Globulin; D013148:Spironolactone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D003534:Cyproterone